Trial Profile
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors Shire; Takeda
- 25 Jan 2024 Planned End Date changed from 15 Dec 2023 to 29 Mar 2024.
- 25 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 29 Mar 2024.
- 24 May 2023 Planned End Date changed from 31 Dec 2022 to 15 Dec 2023.